| Sonstiges: |
- Nachgewiesen in: USPTO Patent Applications
- Sprachen: English
- Document Number: 20170087244
- Publication Date: March 30, 2017
- Appl. No: 15/265545
- Application Filed: September 14, 2016
- Assignees: MERIAL, INC. (DULUTH, GA, US)
- Claim: 1. A combination vaccine comprising a virus-like particle (VLP) component and a modified-live virus (MLV) component, wherein both the VLP and the MLV are directed against the same pathogen or disease, and wherein the combination vaccine overcomes maternally-derived antibodies (MDA).
- Claim: 2. The combination vaccine of claim 1, which provides protective immunity with a single dose.
- Claim: 3. The combination vaccine of claim 1, wherein the pathogen or disease is canine parvovirus (CPV).
- Claim: 4. The combination vaccine of claim 1, wherein the pathogen or disease is foot-and-mouth disease virus (FMDV).
- Claim: 5. The combination vaccine of claim 3, wherein the VLP component of the combination comprises at least at least 10% CPV VLPs (w/w) as a function of total protein content.
- Claim: 6. The combination vaccine of claim 5, wherein the VLP component comprises at least 20% CPV VLPs (w/w).
- Claim: 7. The combination vaccine of claim 3, wherein the CPV VLP is expressed by a baculovirus vector in insect cells.
- Claim: 8. The combination vaccine of claim 3, wherein the CPV VLP comprises at least one CPV capsid protein.
- Claim: 9. The combination vaccine of claim 3, wherein the CPV VLP comprises a CPV polypeptide having the sequence as set forth in SEQ ID NO: 1, 3, 4, 6, 8, 9 or 10; or, wherein the CPV VLP comprises a CPV polypeptide having at least 90% identity a sequence as set forth in SEQ ID NO: 1, 3, 4, 6, 8, 9 or 10.
- Claim: 10. The composition or vaccine of claim 1, wherein the CPV VLP comprises a CPV polypeptide encoded by a polynucleotide having the sequence as set forth in SEQ ID NO: 2, 5 or 7; or, wherein the CPV VLP comprises a CPV polypeptide encoded by a polynucleotide having at least 90% identity to a sequence as set forth in SEQ ID NO: 2, 5 or 7.
- Claim: 11. The combination vaccine of claim 1, wherein the composition or vaccine is not adjuvanted and optionally comprises a pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle.
- Claim: 12. A plasmid useful for producing CPV VLP, comprising a polynucleotide encoding a CPV antigen having a sequence as set forth in SEQ ID NO: 1, 3, 4, 6, or 8-10, or a polynucleotide sequence having at least 90% identity to a sequence as set forth in SEQ ID NO: 1, 3, 4, 6, or 8-10.
- Claim: 13. The plasmid of claim 12, wherein the polynucleotide comprises or consists of the sequence as set forth in SEQ ID NO: 2, 5, 7, 11 or 12.
- Claim: 14. The plasmid of claim 12, wherein the plasmid consists of the sequence as set forth in SEQ ID NO: 11 or 12.
- Claim: 15. The plasmid of claim 12, which is stably transformed into an insect cell, which expresses CPV VLPs.
- Claim: 16. A substantially purified CPV empty capsid or CPV VLP expressed in insect cells, wherein the CPV empty capsid or VLP comprises a polypeptide having a sequence as set forth in SEQ ID NO: 1, 3, 4, 6, or 8-10; or, wherein the CPV empty capsid or VLP comprises a polypeptide having at least 90% identity to a sequence as set forth in SEQ ID NO: 1, 3, 4, 6, or 8-10; or,
- Claim: 17. The purified CPV empty capsid or CPV VLP of claim 16, wherein the CPV empty capsid or VLP consists of a polypeptide having a sequence as set forth in SEQ ID NO: 1, 3, 4, 6, or 8-10.
- Claim: 18. A method of eliciting an immune response in an animal against CPV comprising administering to the animal the composition of any one of claims 1-7, or the CPV empty capsids or VLPs of claim 16.
- Claim: 19. The method of claim 18, wherein the immune response is protective, and wherein the protective immune response protects vaccinates against subsequent exposure to virulent CPV.
- Claim: 20. The method of claim 19, wherein the protective immune response is elicited in the vaccinated animals, regardless of the presence in said animals of high levels of maternally-derived antibodies (MDA) against CPV.
- Current International Class: 61; 07; 12; 61
|
